Positive Outlook for United Therapeutics Driven by Tyvaso Growth and IPF Potential

In a report released yesterday, Roanna Ruiz from Leerink Partners maintained a Buy rating on United Therapeutics, with a price target of $408.00.

Roanna Ruiz’s rating is based on several strategic factors that highlight the potential growth and stability of United Therapeutics. The company is expected to see meaningful growth in its Tyvaso franchise, particularly in the PH-ILD market, which is anticipated to support the base business. Additionally, the upcoming Phase 3 TETON-2 IPF data, expected in the second half of 2025, is a critical catalyst that could significantly boost the stock if the results are positive.
Moreover, United Therapeutics’ established commercial presence, strong relationships with key physicians, and strategic positioning with payers are expected to mitigate competitive pressures. The potential for IPF to become a new growth area for the company adds to the positive outlook. Despite trimming revenue forecasts slightly due to potential competition, the overall revenue and earnings estimates remain above consensus, supporting the Buy rating.

In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $340.00 price target.

Based on the recent corporate insider activity of 167 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.